Al-Shaheri Fawaz N, Alhamdani Mohamed S S, Bauer Andrea S, Giese Nathalia, Büchler Markus W, Hackert Thilo, Hoheisel Jörg D
Division of Functional Genome Analysis, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, 69120 Heidelberg, Germany; Medical Faculty Heidelberg, Heidelberg University, Im Neuenheimer Feld 672, 69120 Heidelberg, Germany.
Division of Functional Genome Analysis, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, 69120 Heidelberg, Germany.
Cancer Treat Rev. 2021 May;96:102193. doi: 10.1016/j.ctrv.2021.102193. Epub 2021 Mar 24.
Pancreatic cancer is currently the most lethal tumor entity and case numbers are rising. It will soon be the second most frequent cause of cancer-related death in the Western world. Mortality is close to incidence and patient survival after diagnosis stands at about five months. Blood-based diagnostics could be one crucial factor for improving this dismal situation and is at a stage that could make this possible. Here, we are reviewing the current state of affairs with its problems and promises, looking at various molecule types. Reported results are evaluated in the overall context. Also, we are proposing steps toward clinical utility that should advance the development toward clinical application by improving biomarker quality but also by defining distinct clinical objectives and the respective diagnostic accuracies required to achieve them. Many of the discussed points and conclusions are highly relevant to other solid tumors, too.
胰腺癌是目前最致命的肿瘤类型，且病例数正在上升。它很快将成为西方世界癌症相关死亡的第二大常见原因。死亡率接近发病率，确诊后的患者生存率约为五个月。基于血液的诊断可能是改善这种严峻状况的一个关键因素，并且正处于有可能实现这一目标的阶段。在此，我们回顾当前的状况及其问题与前景，审视各种分子类型。在整体背景下评估已报道的结果。此外，我们还提出了迈向临床应用的步骤，这些步骤应通过提高生物标志物质量，以及明确不同的临床目标和实现这些目标所需的各自诊断准确性，来推动向临床应用的发展。许多讨论的要点和结论对其他实体瘤也高度相关。
